{
    "Case ID": "065255",
    "Crime_Name": [
        "Patent Infringement"
    ],
    "Crime_Type": [
        "Property Crimes"
    ],
    "Dispute_Type": [
        "Patent validity and infringement"
    ],
    "Legal_Issue": [
        "Whether Mylan's formulation infringes the '948 Patent and whether the '948 Patent is invalid for obviousness"
    ],
    "Governing_Law": [
        "Section 28.3 of the Patent Act"
    ],
    "Procedural_Stage": [
        "Application to prohibit Notice of Compliance"
    ],
    "Evidence_Assessment": [
        "Expert testimonies, formulation specifics, particle size measurements, excipient usage, prior art"
    ],
    "Decision_Outcome": [
        "Application dismissed"
    ],
    "Burden_of_Proof": [
        "On Mylan to establish non-infringement and invalidity"
    ],
    "Credibility_Factor": [
        "Expert testimony evaluated by court"
    ],
    "Legal_Rule": [
        "A patent is invalid if it is obvious based on prior art as of the claim date"
    ],
    "Standard_of_Review": [
        "Obviousness based on person skilled in the art and common general knowledge"
    ],
    "Procedural_Issue": [
        "Analysis of NOC application under patent linkage regime"
    ],
    "Grounds_for_Claim": [
        "Non-infringement and invalidity due to obviousness"
    ],
    "Outcome_on_Merits": [
        "Mylan's allegations of non-infringement justified; patent found invalid"
    ],
    "Decision_Maker": [
        "Court"
    ],
    "Judicial_Review_Outcome": [
        "No prohibition granted to Lilly"
    ],
    "Review_Standard": [
        "Objective assessment of obviousness and claim construction"
    ],
    "Procedural_Fairness_Assessment": [
        "Full evidentiary hearing with expert evidence considered"
    ],
    "Key_Evidence_Considered": [
        "Particle size differences, hydrophilic binder composition, prior art on tadalafil solubility, standard formulation practices"
    ],
    "Legal_Framework": [
        "Patent Act, Canadian pharmaceutical regulatory framework"
    ],
    "Applicant_Challenge": [
        "Lilly sought to block Mylanâ€™s generic product approval"
    ],
    "Court_Result": [
        "Mylan can proceed without restriction by the '948 Patent"
    ],
    "Legal_Rule_Source": [
        "Statutory (Patent Act) and case law principles of obviousness"
    ],
    "Standard_of_Proof": [
        "Balance of probabilities"
    ],
    "Defendant_Response": [
        "Non-infringement and patent invalidity arguments"
    ],
    "Evidence_Type": [
        "Documentary evidence, expert reports, technical data"
    ],
    "Remedy_Requested": [
        "Prohibition of Notice of Compliance issuance to Mylan"
    ],
    "Outcome": [
        "Dismissal of Lilly's application"
    ],
    "Decision_Authority": [
        "Federal Court (implied from context)"
    ],
    "Remedy_Sought": [
        "Interlocutory injunction to prevent market entry"
    ],
    "Resolution_Mechanism": [
        "Judicial determination on patent claims"
    ],
    "Legal_Provision": [
        "Section 28.3, Patent Act"
    ],
    "Authority": [
        "Canadian courts"
    ],
    "Claimant_Status": [
        "Patent holder (Lilly Canada Inc.)"
    ],
    "Legal_Provision_Cited": [
        "Section 28.3 of the Patent Act"
    ],
    "Grounds_for_Inadmissibility_or_Allegation": [
        "Obviousness, lack of inventive step, non-infringement"
    ],
    "Applicable_Process": [
        "Notice of Compliance (NOC) proceeding under PM(NOC) Regulations"
    ],
    "Outcome_of_Review": [
        "Patent found invalid and not infringed"
    ],
    "Pending_Relief_or_Application": [
        "Application to prohibit generic approval"
    ],
    "Jurisdiction": [
        "Canada"
    ],
    "Governing_Rule": [
        "Obviousness test under Section 28.3: whether invention would have been obvious to a person skilled in the art"
    ]
}